Heterocyclyl-ergoline derivatives as 5-HT.sub.1A receptor ligands
    59.
    发明授权
    Heterocyclyl-ergoline derivatives as 5-HT.sub.1A receptor ligands 失效
    杂环基麦角灵衍生物作为5-HT1A受体配体

    公开(公告)号:US06087371A

    公开(公告)日:2000-07-11

    申请号:US125108

    申请日:1998-08-17

    CPC分类号: C07D457/02 C07D457/00

    摘要: Ergoline derivative having formula (I) wherein R.sub.1 is hydrogen atom or C.sub.1-4 alkyl group; R.sub.2 is hydrogen, chlorine, or bromine atom, methyl or C.sub.1-4 alkylthio group; n is 0, 1 or 2; the substituent at position 8 is in .alpha. or .beta. configuration; Het represents an aromatic 5-membered heterocyclic ring, said ring having three heteroatoms which are the same or different and which are selected from the group consisting of sulfur, oxygen and nitrogen atom and X is hydrogen, chlorine or bromine or fluorine atom, or a pharmaceutically acceptable acid addition salt thereof are active at the Central Nervous System level. A process for their preparation is also described, as are pharmaceutical compositions containing them. ##STR1##

    摘要翻译: PCT No.PCT / EP97 / 00582 Sec。 371日期1998年8月17日 102(e)日期1998年8月17日PCT 1997年2月7日提交PCT公布。 公开号WO97 / 30050 PCT 日期:1997年8月21日具有式(I)的衍生物,其中R 1为氢原子或C 1-4烷基; R2是氢,氯或溴原子,甲基或C1-4烷硫基; n为0,1或2; 位置8处的取代基是α或β构型; Het表示芳族5元杂环,所述环具有三个相同或不同的杂原子,选自硫,氧和氮原子,X是氢,氯或溴或氟原子,或 其药学上可接受的酸加成盐在中枢神经系统水平上是有活性的。 还描述了其制备方法,以及含有它们的药物组合物。

    Substituted kynurenines and process for their preparation
    60.
    发明授权
    Substituted kynurenines and process for their preparation 失效
    替代的犬尿苷及其制备方法

    公开(公告)号:US5786508A

    公开(公告)日:1998-07-28

    申请号:US411656

    申请日:1995-04-06

    CPC分类号: C07C229/36 C07C2101/14

    摘要: The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT). The present invention also provides, as novel compounds, a selected class of KAT inhibitors which are the compounds of formula (IA) ##STR1## wherein R is halogen, C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.7 cycloalkyl, phenyl-C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.6 -C.sub.10 aryloxy, phenyl-C.sub.1 -C.sub.4 alkoxy or trifluoromethyl, and R.sub.1 is hydroxy, C.sub.1 -C.sub.6 alkoxy, amino, mono-C.sub.1 -C.sub.6 alkylamino, di-C.sub.1 -C.sub.6 alkylamino, hydroxylamino, C.sub.1 -C.sub.4 alkoxyamino or benzyloxyamino, with the provisos that: (i) when R.sub.1 is hydroxy and, at the same time, R is halogen, then this halogen is not fluorine; and (ii) when R.sub.1 is hydroxy and, at the same time, R is C.sub.1 -C.sub.6 alkyl, then this C.sub.1 -C.sub.6 alkyl is not methyl, either as a single isomer or as a mixture of isomers, and the pharmaceutically acceptable salts thereof.

    摘要翻译: PCT No.PCT / US94 / 07804 Sec。 371日期:1995年4月6日 102(e)日期1995年4月6日PCT 1994年7月15日PCT公布。 公开号WO95 / 04714 日期1995年2月16日本发明涉及用作治疗与作为犬尿氨酸转氨酶(KAT)酶抑制剂的化合物的脑老化过程和围产期脑疾病相关的认知障碍的用途。 本发明还提供作为新化合物的选择类别的作为式(IA)化合物的KAT抑制剂,其中R是卤素,C 1 -C 6烷基,C 5 -C 7环烷基,苯基-C 1 -C 4烷基, C 1 -C 6烷氧基,C 6 -C 10芳氧基,苯基-C 1 -C 4烷氧基或三氟甲基,R 1是羟基,C 1 -C 6烷氧基,氨基,单-C 1 -C 6烷基氨基,二-C 1 -C 6烷基氨基,羟基氨基,C 1 -C 4 烷氧基氨基或苄氧基氨基,条件是:(ⅰ)当R 1为羟基,同时R为卤素时,该卤素不为氟; 和(ii)当R 1是羟基,并且同时R是C 1 -C 6烷基时,则该C 1 -C 6烷基不是甲基,作为单一异构体或作为异构体的混合物,以及其药学上可接受的盐 。